February 9, 2021
VIA EDGAR
Ada D. Sarmento
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re: | Oramed Pharmaceuticals Inc. |
Registration Statement on Form S-3 | |
File No. 333-252696 |
Dear Sir or Madam:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Oramed Pharmaceuticals Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 9:00 a.m., Eastern Time, on February 10, 2021, or as soon as practicable thereafter.
The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Oded Har-Even of Sullivan & Worcester LLP at (212) 660-5002 and that such effectiveness also be confirmed in writing.
Very truly yours, | |||
Oramed Pharmaceuticals Inc. | |||
By: | /s/ Avraham Gabay | ||
Name: | Avraham Gabay | ||
Title: | Chief Financial Officer |